Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Excellent summary, biodoc! I think the increased enrollment pace (about 30-40 patients in five months) was mostly influenced by the encouraging interim result. Leo said there was a great deal of competition for OM patients. When patients decide to participate in a trial, their doctors will present them with a list of choices. The 7 out of 9 severe OM prevention definitely made the decision easy for them. This bodes well for Phase 3 enrollment if top-line data are positive as well.